Meropenem Qilu

Meropenem, the active ingredient in Meropenem Qilu, is a carbapenem antibiotic presented as a sterile solution for intravenous use. It treats a range of serious bacterial infections in adult and pediatric patients when other therapies are unsuitable. GNH USA supplies Meropenem Qilu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections affecting various organ systems. - Complicated intra‑abdominal infections: provides rapid bacterial eradication and clinical cure. - Complicated urinary tract infections: eliminates resistant uropathogens and resolves infection. - Skin and soft tissue infections: penetrates tissue to treat deep‑seated bacterial involvement. - Community‑acquired and hospital‑acquired pneumonia: covers typical and atypical pathogens causing severe lung infection. - Meningitis: achieves therapeutic concentrations in cerebrospinal fluid to treat central nervous system infections. - Septicemia: rapidly reduces bloodstream bacterial load and improves survival outcomes.

Adverse reactions may occur with any intravenous antibiotic.

Common Side Effects: - Diarrhea: mild to moderate loose stools. - Nausea: transient feeling of queasiness. - Headache: occasional mild cranial discomfort. - Injection site pain: local discomfort during infusion. - Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects: - Severe hypersensitivity: rash, bronchospasm, or anaphylaxis. - Clostridioides difficile colitis: watery diarrhea with possible pseudomembranous colitis. - Seizures: especially in patients with renal impairment or high doses. - Renal dysfunction: rise in serum creatinine or reduced urine output.

Before initiating therapy, consider patient‑specific factors and monitor for adverse events. - Renal function: adjust dose in patients with impaired clearance. - Allergies: avoid in individuals with known β‑lactam hypersensitivity. - Pregnancy: use only if benefits outweigh potential risks, as safety data are limited. - Concomitant nephrotoxins: monitor kidney function when combined with other renal‑impacting drugs. - Therapeutic drug monitoring: consider in critically ill or renal‑compromised patients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may alter the efficacy or toxicity of co‑administered medicines.

Major Interactions (Avoid): - Valproic acid: risk of reduced serum levels and loss of seizure control. - Probenecid: may increase meropenem concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxicity; monitor renal parameters. - Loop diuretics: potential for increased ototoxicity when combined with other ototoxic agents. - Anticoagulants: possible alteration of INR; check coagulation status regularly.